5:02 PM
 | 
Jul 10, 2013
 |  BC Extra  |  Clinical News

Roche drops aleglitazar

Roche (SIX:ROG; OCTQX:RHHBY) discontinued development of aleglitazar after an independent DSMB recommended stopping early the Phase III AleCardio trial evaluating the diabetes compound due...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >